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M A J O R A R T I C L E
Incidence and Severity of Respiratory Syncytial Virus
Pneumonia in Rural Kenyan Children Identified
through Hospital Surveillance
D. James Nokes,1,2 Mwanajuma Ngama,1 Anne Bett,1 John Abwao,1 Patrick Munywoki,1 Mike English,1,3
J. Anthony G. Scott,1,4 Patricia A. Cane,5 and Graham F. Medley2
1Kenya Medical Research Institute, Centre for Geographic Medicine Research-Coast, Kilifi, Kenya; and 2Department of Biological Sciences,
University of Warwick, Coventry, 3Department of Paediatrics, Oxford University, and 4Nuffield Department of Medicine, University of Oxford,
Oxford, and 5Health Protection Agency, London, United Kingdom
Background. Although necessary for developing a rationale for vaccination, the burden of severe respiratory
syncytial virus (RSV) disease in children in resource-poor settings remains poorly defined.
Methods. We conducted prospective surveillance of severe and very severe pneumonia in children aged !5
years admitted from 2002 through 2007 to Kilifi district hospital in coastal Kenya. Nasal specimens were screened
for RSV antigen by immunofluorescence. Incidence rates were estimated for the well-defined population.
Results. Of 25,149 hospital admissions, 7359 patients (29%) had severe or very severe pneumonia, of whom
6026 (82%) were enrolled. RSV prevalence was 15% (20% among infants) and 27% during epidemics (32% among
infants). The proportion of case patients aged 3 months was 65%, and the proportion aged 6 months was
43%. Average annual hospitalization rates were 293 hospitalizations per 100,000 children aged !5 years (95%
confidence interval, 271–371 hospitalizations per 100,000 children aged !5 years) and 1107 hospitalizations per
100,000 infants (95% confidence interval, 1012–1211 hospitalizations per 100,000 infants). Hospital admission
rates were double in the region close to the hospital. Few patients with RSV infection had life-threatening clinical
features or concurrent serious illnesses, and the associated mortality was 2.2%.
Conclusions. In this low-income setting, rates of hospital admission with RSV-associated pneumonia are
substantial; they are comparable to estimates from the United States but considerably underestimate the burden
in the full community. An effective vaccine for children aged 12 months (outside the age group of poor responders)
could prevent a large portion of RSV disease. Severity data suggest that the justification for RSV vaccination will
be based on the prevention of morbidity, not mortality.
Respiratory syncytial virus (RSV) is a major cause of
severe pneumonia and bronchiolitis in infants and chil-
dren worldwide and is seen as an important target for
a pediatric vaccine [1–3]. Much attention has focused
on developing a live, attenuated RSV vaccine for ad-
ministration during early infancy, with some encour-
aging results reported on the safety and immunoge-
nicity of recent candidates [1, 4, 5]. In addition to
research in vaccine design and development, a suc-
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cessful intervention program needs (1) an accurate es-
timate of disease burden in the target population and
(2) a comprehensive description of the epidemiology
of infection and disease to optimize control strategies
and estimate their potential impact. Both of these ob-
jectives can be reached through hospital-based sur-
veillance for RSV disease within a well-defined popu-
lation. Furthermore, long-term disease monitoring es-
tablishes the necessary baseline information by which
to assess the impact and effectiveness of interventions.
In the developing world, hospital-based surveillance of
RSV disease has been performed infrequently, mainly
without an accurate population base, and surveillance
has rarely been sustained [6–8]. In this study, we present
the results of prospective population-based surveillance
for RSV disease spanning 6 years at a rural district
hospital typical of tropical sub-Saharan Africa.
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Figure 1. Flow diagram of recruitment and sample testing of children aged !5 years (left) and infants (right) admitted to Kilifi District Hospital
from January 2002 through December 2007. Tested children refers to those who were enrolled and had a sample collected and tested, with the
remainder either not enrolled or enrolled with a sample not taken and tested. Percentages in brackets within a box refer to the proportion of individuals
from the preceding box. Note that, among those who were untested who refused participation, 121 children aged !5 years and 90 infants subsequently
died, and these patients contribute to the denominator of the case fatality ratio (CFR). RSV, respiratory syncytial virus.
METHODS
Study location and population. Surveillance was undertaken
at Kilifi District Hospital (KDH), which is situated in the town
of Kilifi in coastal Kenya and serves as a primary care and
referral facility for the predominantly rural farming popula-
tion of around 500,000 persons, of whom 18% are aged !5
years [9]. The District has one of the lowest average per cap-
ita incomes in Kenya, and mortality rates among those aged
!5 years and infants (aged !1 year) are high (141 and 85
deaths per 100,000 persons, respectively [9]), although there is
considerable geographical variability. Malaria is transmitted
throughout the year, with peaks in transmission during No-
vember-January and May-August following the rainy season,
but the incidence of malaria has decreased sharply in recent
years [10]. Human immunodeficiency virus type 1 (HIV-1)
prevalence in women attending KDH antenatal care in 2004
was ∼5% [11]. There are ∼5000 pediatric hospital admissions
(upper age, 12 years) each year. Each child is investigated with
a standard computerized clinical history and examination and
standard set of investigations on hospital admission, including
a full hemogram, blood culture, and among febrile children, a
Giemsa-stained blood sample slide [12]. In 2000, a demo-
graphic surveillance study was established in an area of 891
km2 close to KDH, to monitor births, deaths, and migration
events in a population of ∼240,000 persons through 4-month-
ly enumeration rounds. From 16 April 2002, the residency sta-
RSV Pneumonia in Kenyan Children • CID 2009:49 (1 November) • 1343
Figure 2. Seasonal variation in monthly admissions to Kilifi District
Hospital of children aged !5 years over the period from January 2002
through December 2007 and corresponding meteorological recordings.
Table 1. Age Distribution of Admissions due to Respiratory Syncytial Virus (RSV)–Associated Pneumonia at Kilifi District Hospital,
2002–2007, Stratified by Severity
Age
class,
months
Severe pneumonia Very severe pneumonia All cases
No.
tested
Positive
result
Percentage
positive
in age class
Percentage
positive
overall
No.
tested
Positive
result
Percentage
positive
in age class
Percentage
positive
overall
No.
tested
Positive
result
Percentage
positive
in age class
Percentage
positive
overall
0–2 1210 255 21.1 33.0 311 57 18.3 50.9 1521 312 20.5 35.3
3–5 761 169 22.2 21.9 151 19 12.6 17.0 912 188 20.6 21.3
6–11 1023 183 17.9 23.7 253 14 5.5 12.5 1276 197 15.4 22.3
12–23 994 101 10.2 13.1 258 14 5.4 12.5 1252 115 9.2 13.0
24–35 388 47 12.1 6.1 198 4 2.0 3.6 586 51 8.7 5.8
36–59 307 17 5.5 2.2 172 4 2.3 3.6 479 21 4.4 2.4
All 4683 772 16.5 100.0 1343 112 8.3 100.0 6026 884 14.7 100.0
tus of each child presenting to KDH was established on hos-
pital admission through linkage to the population register of
the Kilifi Epidemiological and Demographic Surveillance Study
(EpiDSS) [12].
Patients. Surveillance for RSV was initiated on 1 January
2002. We report on all children aged 1 day to 59 months who
presented with the clinical syndrome of pneumonia, either se-
vere or very severe, excluding babies with neonatal tetanus.
Clinical definitions, which follow, have been described else-
where [12, 13]. A history of cough or difficulty in breathing
for !30 days, when accompanied by lower chest wall indrawing,
was defined as severe pneumonia. A history of cough or dif-
ficulty in breathing for !30 days, when accompanied by any 1
of prostration, coma, or hypoxemia was defined as very severe
pneumonia. Prostration included the inability to feed or drink.
Hypoxemia was defined by an oxygen saturation level (pO2)
of !90% determined by finger tip Oxymeter (Nelcor). All chil-
dren with hypoxemia at hospital admission are given supple-
mental oxygen. Malaria was defined by Plasmodium falciparum
parasitemia observed on the blood sample slide. Severe mal-
nutrition was defined as a small value (10th percentile by age
group) for mid-upper arm circumference, bipedal edema, or
visible severe wasting. Shock was determined by a peripheral-
central temperature gradient, a capillary refill time of 13 s, or
a weak peripheral pulse volume. A history of premature birth
was elicited for all infants at hospital admission, and a history
of heart disease was established from diagnosis-on-discharge
data. Bronchiolitis as a specific condition is not reported; in
this setting, it has little influence on patient management and,
despite the long-term surveillance, remains poorly recognized
by clinicians at hospital admission (in the absence of laboratory
confirmation of RSV). HIV diagnostic counseling and testing
was not in place for most of the period of surveillance cov-
ered in this report and is not considered here. Written informed
consent was obtained for all eligible participants.
Nasal specimens were collected as soon as possible after hos-
pital admission by nasal washing; in children who were too un-
well to undergo nasal washing, a nasaopharyngeal aspirate was
performed [14]. Sample collection was postponed to the follow-
ing Monday for children admitted over the weekend (beginning
Friday at 5 PM). Specimens were processed as described else-
where [15] and were screened for RSV antigen by use of a Di-
rect Immunofluorescent Antibody Test (Light Diagnostics RSV
screen; Chemicon), according to the manufacturer’s protocol.
The Kenyan National Research Ethical Committee and the Cov-
entry Research Ethics Committee (United Kingdom) granted
ethical approval for the study.
Data analysis. Data obtained at hospital admission and
demographic data were entered into FileMaker, version 5.5
(FileMaker), and were cleaned and analyzed using STATA, ver-
sion 10.1 (StataCorp). Throughout, the term pneumonia refers
to all cases of clinically severe or very severe pneumonia. The
pattern of admission to the hospital with RSV-associated pneu-
monia was determined from January 2002 through December
2007, and the incidence of admission to the hospital with RSV-
associated pneumonia was determined from May 2002 through
April 2007. The incidences and 95% confidence intervals (CIs)
were calculated as the mean annual number of resident children
admitted with each case definition divided by the resident pop-
ulation size at the mid-point of the study period (29 October
2004), adjusted for the estimated proportion of these patients
with detectable RSV in their nasal specimens. This assumes that
the proportion of children with pneumonia who had RSV in
their nasal specimens was the same in both the tested and
untested groups. Annual period incidence estimates (eg, for the
year from May 2002 through April 2003) were calculated using
1344 • CID 2009:49 (1 November) • Nokes et al
Table 2. Estimated Rates of Hospitalization (Hospitalizations per 100,000 Persons per Year) with Respiratory Syncytial Virus (RSV)–
Associated Pneumonia to Kilifi District Hospital over the Period from 1 May 2002 through 30 April 2007, by Age and Severity
Age class and
pneumonia severity
No. of
cases
No. of
persons
tested for RSV
No. (%) of
persons
positive for RSV
Person-years of
observation
LRTI
incidence
RSV incidence
(95% CI)
!1 year
Severe 1889 1644 348 (21.2) 42960 4397 931 (844–1027)
Very severe 486 344 50 (14.5) 42960 1131 164 (130–208)
Severe or very severe 2375 1988 398 (20.0) 42960 5528 1107 (1012–1211)
!5 years
Severe 3037 2647 447 (16.9) 209075 1453 245 (225–267)
Very severe 961 680 63 (9.3) 209075 460 43 (35–52)
Severe or very severe 3998 3327 510 (15.3) 209075 1912 293 (271–317)
NOTE. The estimated resident population for the specified age class was estimated by multiplying the estimated population at the midpoint of the
study (ie, 29 October 2004) by 5 (ie, the number of years in the study period). See the Methods section for the definitions used for pneumonia categories
and the incidence estimation procedure. CI, confidence interval; LRTI, lower respiratory tract infection.
Table 3. Hospitalization Rates per 100,000 Children by
Year of Surveillance and Stratified by Age Group for
Cases of Severe or Very Severe Pneumonia and Cases
of Respiratory Syncytial Virus (RSV)–Associated Severe
or Very Severe Pneumonia
This table is available in its entirety in the online version
of Clinical Infectious Diseases
the resident population denominator for the mid-point of each
period (eg, 30 October 2002). Incidence rates and 95% CIs
were estimated using a normal approximation of the likelihood
profile [16].
Geographical variation in the incidence of RSV-associated
admissions was calculated for each administrative sub-location
(of which there are 40 in Kilifi EpiDSS) and was presented as
a categorical variable with use of ArcView ArcMap, version 9.2
(ESRI), and Adobe Illustrator CS2, version 12.1 (Adobe). The
incidence was calculated separately for sub-locations that are
close to the hospital, meaning that at least part of the sub-
location fell within a radius of 5 km of KDH [12]. RSV epidemic
periods were empirically defined to begin when at least 10%
of tested samples were RSV positive or with the observation of
at least 2 cases of RSV infection per week in each of 2 con-
secutive weeks and were defined to continue as long as these
conditions were satisfied, with the requirement that an epi-
demic must last for 4 weeks. Proportions were compared
using Fisher’s exact or x2 tests (2 tailed), and equality of dis-
tributions was evaluated using the Wilcoxon rank-sum test. Ad-
justed risk ratios were determined using binomial regression.
RESULTS
From 1 January 2002 through 31 December 2007, 25,149 chil-
dren aged !5 years, including 11,829 infants, were admitted to
KDH (Figure 1). Of the 7359 eligible children, 6026 (82%)
were enrolled, of whom, 884 (15%) had positive test results for
RSV (there was no difference by sex). The reasons for nonen-
rollment were early discharge, refusal, and death, in an ap-
proximate ratio of 2:1:1. Comparing children who were and
who were not enrolled, there was no difference in the median
age (9 months) or in the percentage with male sex (56%), and
the proportion of infants was higher in the enrolled group (59%
vs 56%; ). The rate of nonenrollment was higher notPp .037
during than during RSV epidemics (20% vs 16%; , byP ! .001
Fisher’s exact test). Among the enrolled patients, 4.4% died in
the hospital, compared with 9.9% of all eligible children. Fur-
thermore, for those enrolled in the study, there was a low-
er proportion with malaria parasitemia at hospital admission
(16% vs 21%; ), with a pathogenic bacterial isolateP ! .001
(5.4% vs 11%; , by Fisher’s exact test), and with veryP ! .001
severe pneumonia (22% vs 46%; , by Fisher’s exact test),P ! .001
but there was no difference in the proportion with severe mal-
nutrition (14% vs 16%; , by Fisher’s exact test).Pp .058
Epidemiology. Epidemics of RSV-positive case patients
were periodic with a starting date from November through
February, a peak month from January through May, and an
average duration of 18 weeks (range, 13–27 weeks). Epidemics
appear not to have a simple annual pattern, but rather, the
interepidemic period (from peak month to peak month) al-
ternates between 9 and 15 months (Figure 2). Of all hospital
admissions of patients with RSV-associated pneumonia, 815
(92%) occurred during an epidemic period. The number of
RSV cases occurring during each epidemic ranged from 68
(17% of samples tested) in the epidemic of 2002–2003 to 202
(30% of samples tested) in 2005–2006, with an overall pro-
portion of 27%. Seasonal variation in hospital admissions with
RSV infection roughly coincided with the variation in total
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Figure 3. Geographical variation within the Kilifi Health and Demographic Surveillance System in the incidence of respiratory syncytial virus (RSV)–
associated severe or very severe pneumonia among children aged !5 years admitted to Kilifi District Hospital (KDH). Incidence is presented as the
number of hospitalizations per 100,000 children aged !5 years admitted per year for the 5-year period from May 2002 through April 2007, categorized
into 4 levels (see numerical ranges) and stratified by administrative sublocation. Main roads, Kilifi Creek (C), and KDH (H) are identified. The zone
marked by a white perimeter has a 5-km radius from its central point (KDH).
pneumonia admissions. No temporal association with any me-
teorological measure or other disease syndrome was observed
(Figure 2).
The distribution of hospital admissions with RSV-associated
pneumonia by age and severity is presented in Table 1. The
proportion of patients with positive results for RSV within an
age class was highest among children aged 0–5 months (∼21%),
decreased with increasing age, and was higher among children
with severe pneumonia than among those with very severe
pneumonia (16.5% vs 8.3%; ). The proportions of caseP ! .001
patients aged !3, !6, and !12 months were 35%, 57%, and
79%, respectively. The age distribution of case patients differed
1346 • CID 2009:49 (1 November) • Nokes et al
Table 4. Prevalence of Features among Respiratory Syncytial Virus (RSV)–Positive and -Negative Children
Aged !5 Years Admitted to Kilifi District Hospital with Severe or Very Severe Pneumonia, 2002–2007
Characteristic
Percentage of RSV-
positive patients
(n p 884)a
Percentage of RSV-
negative patients
(n p 5142)a
Adjusted RRb
(95% CI) (95%)
Clinical
Crackles 66.7 44.1 1.43 (1.34–1.52)
Wheezing 15.2 11.2 1.43 (1.18–1.73)
Nasal flaring 61.8 48.2 1.16 (1.09–1.24)
Indrawing 98.3 90.2 1.04 (1.03–1.05)
Shockc 13.5 19.4 0.68 (0.56–0.82)
Hypoxemia 10.3 13.7 0.73 (0.59–0.91)
Postrate/unconscious 4.1 13.8 0.36 (0.26–0.50)
Concurrent illness
Slide-positive malaria 4.6 (n p 864) 18.3 (n p 5073) 0.36 (0.26–0.49)
Malnutritiond 6.6 15.4 0.47 (0.36–0.61)
Bacteremia 2.3 (n p 864) 6.0 (n p 5071) 0.4 (0.25–0.63)
Risk factors
Premature (infants) 4.6 (n p 697) 6.7 (n p 3005) 0.67 (0.45– 0.97)
Heart disease 1.0 2.1 0.49 (0.24–1.00)
Outcome
Duration of inpatient stay 112 days 3.8 8.8 0.46e (0.32–0.66)
Died 2.4 4.7 0.41 (0.26–0.64)
NOTE. CI, confidence interval; RR, relative risk.
a Denominator for percentage calculations, unless otherwise specified in parentheses.
b RR of feature in RSV-positive patients, relative to RSV-negative patients, adjusted for age class (with 95% CI).
c Temperature gradient, capillary refill 13 s, or weak pulse volume.
d Small mid-upper arm circumference for age, bipedal edema, or visible severe wasting. Small mid-upper arm circumference
was defined as 10th percentile calculated for all patients admitted to Kilifi District Hospital during 2002–2007, which generated
the following cut-off values by age: 0–5 months, 7.8 cm; 6–23 months, 11.0 cm; 24–35 months, 11.6 cm; 36–59 months,
12.2 cm [12].
e RR was also adjusted for differential mortality between RSV-positive and RSV-negative children.
significantly by clinical category ( ). In particular, theP ! .001
proportion of patients admitted with RSV-associated disease
who were aged 0–2 months was higher (51%) among the subset
of children with very severe pneumonia.
Hospitalization rates. Over the 5 year period from 1 May
2002 through 30 April 2007, the mean annual number of hos-
pital admissions from the community of Kilifi EpiDSS residents
was 2661 for patients aged !5 years and 1188 for patients aged
!1 year. The annual rate of hospital admissions of patients with
severe or very severe pneumonia was 1912 hospitalizations per
100,000 persons for children aged !5 years and 5528 hospi-
talizations per 100,000 persons for infants aged !1 year. The
annual incidence of hospital admission with RSV-associated
severe or very severe pneumonia was 293 hospitalizations per
100,000 persons (range by year of study, 202–373 hospitali-
zations per 100,000 persons) for children aged !5 years and
1107 hospitalizations per 100,000 persons (range, 692–1587
hospitalizations per 100,000 persons) for infants (Table 2). In-
cidence estimates by year of study and finely stratified by age
are provided in Table 3.
The geographical distribution of RSV-associated severe and
very severe pneumonia incidence in children aged !5 years, pre-
sented in Figure 3, reveals considerable variation between ad-
ministrative sub-locations, with incidence apparently decreasing
with distance from the District hospital. For the population of
children aged !5 years living within the region defined as close
to KDH, the annual hospitalization rate for severe or very se-
vere pneumonia was 3169 hospitalizations per 100,000 persons
(95% CI, 3023–3323 hospitalizations per 100,000 persons) and
for RSV-associated severe or very severe pneumonia was 574
hospitalizations per 100,000 persons (95% CI, 507–650 hos-
pitalizations per 100,000 persons). Among infants in the sub-
locations closest to the hospital, the annual incidence of se-
vere or very severe pneumonia and RSV-associated severe or
very severe pneumonia were 8828 (95% CI, 8297–9393 hos-
pitalizations per 100,000 persons) and 2112 hospitalizations
per 100,000 persons (95% CI, 1835–2431 hospitalizations per
100,000 persons), respectively.
Severity and concurrent illnesses. Among patients with
severe or very severe pneumonia, the clinical signs crackles,
wheezing, nasal flaring, and lower chest-wall indrawing were
all associated with RSV infection, whereas shock, hypoxemia,
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prostration, and coma were inversely associated with RSV in-
fection (Table 4). Concurrent malaria parasitemia, severe mal-
nutrition, and bacteremia were all significantly less common
among RSV-positive children with pneumonia. Furthermore,
a history of premature birth among infants and a discharge
diagnosis including heart disease were marginally less frequent
among RSV-positive children. Patients with RSV-associated
pneumonia had a significantly shorter inpatient stay and lower
case fatality rates than did patients with RSV-negative pneu-
monia. RSV-positive patients were significantly younger than
RSV-negative patients (median age, 4.9 vs 19.1 months; zp
, by Wilcoxon rank-sum test; ). Adjusting the rel-11.34 P ! .001
ative risk of each feature in Table 4 for age did not alter these
associations. The proportion of RSV-associated pneumonia
cases in children aged !5 years that were very severe did not
differ by distance from KDH (11.2% near KDH vs 13.5% far
from KDH; , by Fisher’s exact test).Pp .501
Bacterial pathogens were identified in the blood samples of
20 (2%) of 864 RSV-positive patients with pneumonia. Isolates
cultured were Group A b-hemolytic streptococci ( ),np 5
Streptococcus pneumoniae ( ), Acinetobacter species (np 5 np
), Haemophilus influenzae ( ), Pseudomonas species5 np 4
( ), and Escherichia coli ( ). In 1 instance, there wasnp 1 np 1
a coinfection with S. pneumoniae and H. influenzae. Three of
the children with confirmed bacterial coinfection subsequently
died; 2 were infected with H. influenzae, and 1 was infected
with Acinetobacter. In comparison, 6% (302) of RSV-negative
patients had positive blood culture results, with similar mor-
tality (15%) and species distribution relative to RSV-positive
patients.
DISCUSSION
Our surveillance at a district hospital in coastal Kenya spanning
6 years provides a highly detailed description of the burden of
severe RSV disease among young children in a typical rural de-
veloping country setting. Over the period 2002–2007, we iden-
tified clinically severe or very severe pneumonia in roughly one-
third of children aged !5 years and 38% of infants admitted to
KDH, of which an estimated 15% and 19%, respectively, had
pneumonia associated with RSV infection. The rate of hospital
admissions with RSV-associated pneumonia within the demo-
graphically well-defined population was 293 cases per 100,000
patients per year among children aged !5 years and 1107 cases
per 100,000 patients per year among infants. These data are
similar in magnitude to those reported for an intensively mon-
itored birth cohort within the same population (1300 cases of
RSV-associated severe pneumonia in infants admitted to KDH
per 100,000 child-years of observation) [13] and are similar to
the data reported for the small number of other denominator-
based studies of hospital admissions in resource-poor countries
[6, 7]. Furthermore, our reported rates mirror closely popula-
tion-based hospitalization rates recently described for various
locations in the United States [17].
Thus, our data indicate that an effective pediatric RSV vac-
cine could prevent a sizeable proportion of hospital admissions
attributable to pneumonia. A useful reference point is afforded
by comparison with severe rotavirus diarrhea (targeted for vac-
cination [18]), which exhibited an annual rate of hospitaliza-
tion at KDH for the period 2002–2004 of 478 cases per 100,000
patients among children aged !5 years and 1431 cases per
100,000 patients among infants [12]. Furthermore, the distance
decay in rates of hospitalization (Figure 3), reported elsewhere
in The Gambia [8], indicates a large (∼2-fold) additional bur-
den of severe pneumonia due to RSV present in the community
but not recorded through inpatient surveillance. If we assume
the estimates for areas that are close to the hospital are more
realistic of the community burden and representative of Kenya
as a whole, the annual number of cases of RSV-associated severe
or very severe pneumonia among children aged !5 years and
infants throughout the country are estimated to be 37,000 and
29,500, respectively (based on population estimates for children
aged !5 years and births in 2008 of 6.5 and 1.4 million, re-
spectively [19]).
Further, we point out an additional burden of severe pneu-
monia due to RSV in the community, missed by hospital sur-
veillance, in the form of patients presenting to outpatient health
facilities who are not admitted, which was shown in our report
of a birth cohort in the same setting as the present study [13].
A potential additional source of underestimation of RSV disease
in our study arises from the immunofluorescence assay used
to detect the virus, which has been shown to be less sensitive
than molecular detection methods [20, 21].
A clear impediment to vaccine intervention is the absence
of an effective candidate for use in the key target age group of
0–2 months [4, 22]. Nevertheless, studies consistently show
good safety and immunogenicity of live, attenuated RSV vac-
cines in older infants and young children [5, 23]. Data from
the present study show that approximately two-thirds of RSV-
associated pneumonia that results in hospitalization occurs in
children aged 3 months, and therefore, delayed vaccine de-
livery has the potential to prevent a significant fraction of
RSV disease. Reduced transmission from older, vaccinated
infants to vulnerable infants may enhance the benefit of de-
layed vaccination.
Our data show that the incidence of RSV disease varies con-
siderably year-by-year, particularly among infants, where in-
cidence varied by a factor of 12 between the lowest and highest
incidence years, suggesting that short-term studies may present
a biased picture of RSV disease burden. Interestingly the dis-
tribution of disease by age was roughly constant over time (in
contrast to observations made in The Gambia [24]).
In relation to pneumonia severity, our study shows that non–
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life-threatening clinical features were more strongly associated
with being RSV positive than RSV negative, whereas the risks
of very severe conditions, risk factors, and concurrent illness
were significantly higher among RSV-negative patients. A sim-
ilar clinical pattern was reported in an in-patient study per-
formed in Mozambique [25]. The low case fatality rate of 2.2%
for RSV-positive patients (in line with most other reports [6,
26, 27]), compared with 4.7% for RSV-negative patients, is
therefore not surprising. These data support the rationale for
an RSV vaccine on the basis of prevention of morbidity rather
than mortality. Nevertheless, as in other studies, there is some
concern regarding bias in sampling of less severe cases [6],
because 18% of eligible children were not tested, and the case
fatality among the enrolled patients was less than one-half that
observed among all eligible children (4.4% vs 9.9%). In our
setting, faced with a child undergoing emergency treatment, it
was not a clear priority for the clinician to collect a nasal sample.
Therefore, it is possible that the true case fatality rate associated
with RSV is significantly higher than that observed, and con-
sideration should be given to collecting a specimen post-mor-
tem to address this unknown factor.
The prospect of widespread use of vaccines against H. influ-
enza type b and S. pneumoniae across the developing world is
set to substantially alter the landscape of pneumonia etiology
[3]. Surveillance for a broad etiology of the remaining signif-
icant burden of childhood pneumonia is of increasing impor-
tance. Arguably, the most important remaining cause of child-
hood pneumonia that is potentially preventable by vaccine
intervention is RSV. The present study reports a substantial
burden of RSV-associated severe pneumonia in a low-income
setting that is equivalent to that identified in the high-income
setting. This argues for a need to investigate the potential use
of vaccines for both developed and developing countries. This
study also demonstrates the power of long-term surveillance
in understanding the role of RSV in morbidity and mortality
patterns in children in a low-resource setting and the require-
ment for population evidence in developing a rational strategy
for future RSV vaccine intervention.
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